Targeting other abnormal signaling pathways in sarcoma: EGFR in synovial sarcomas, PPAR-gamma in liposarcomas

Cancer Treat Res. 2004:120:151-67. doi: 10.1007/1-4020-7856-0_9.
No abstract available

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Enzyme Inhibitors / therapeutic use
  • ErbB Receptors / metabolism*
  • Humans
  • Liposarcoma / metabolism
  • Liposarcoma / pathology
  • Liposarcoma / therapy*
  • Oncogene Proteins, Fusion / metabolism
  • Receptors, Cytoplasmic and Nuclear / metabolism*
  • Sarcoma, Synovial / metabolism
  • Sarcoma, Synovial / pathology
  • Sarcoma, Synovial / therapy*
  • Signal Transduction / drug effects*
  • Transcription Factors / metabolism*

Substances

  • Antineoplastic Agents
  • Enzyme Inhibitors
  • Oncogene Proteins, Fusion
  • Receptors, Cytoplasmic and Nuclear
  • Transcription Factors
  • ErbB Receptors